Answers are grounded in this paper and cite their sources.
Randomized trial assesses safety and pharmacodynamics of MD-18 in healthy volunteers, indicating potential benefits for obesity and diabetes.
Introduction and Objective: PTP-1B is a promising target for obesity and type 2 diabetes that is challenged by off-target effects of small molecules. MD-18 is a small peptide that disrupts the binding of a partner protein (Nck1) and thereby specifically inhibits PTP-1B activity. Subcutaneous MD-18 induced weight and fat loss in obese mice with preservation of lean mass and functioned as an insulin sensitizer in diabetic mice, with no observed toxicity in chronic GLP studies in rats and dogs. Accordingly, the objective of this study was to assess the safety, tolerability and pharmacodynamic profile of MD-18 in a first-in-human study. Methods: A randomized, placebo-controlled single-ascending trial was conducted in 35 healthy volunteers randomized across five cohorts assessing a dose range of 40-320 mg. 25 subjects were dosed sc with MD-18 and 10 with placebo and followed for 7-days post-dose. Results: MD-18 was well-tolerated, with no safety signals or drug-associated adverse events other than injection site reaction (grade 1) that resolved rapidly in all cases. MD-18 treatment resulted in significant appetite suppression (p=0.034) and improvements in insulin sensitivity (HOMA2IR)(p<0.03) 7-days following a single dose that was driven by decreased insulin (p=0.02). Among subjects with leptin above a 2.5 ng/mL threshold (n=12) there was a significant decrease in leptin (p=0.04) suggestive of an effect on adiposity, while the full cohort exhibited a trend (p=0.08). MD-18 significantly reduced ALT with no effect on other liver enzymes and reduced LDL- and total cholesterol by ~10 mg/dL (p<0.005). The multiple ascending dose study will also be presented. Conclusion: MD-18 appears safe and well-tolerated, with multiple cardiometabolic signals 7-days following a single dose. Disclosure A. Tirosh: Advisory Panel; Current; Medtronic. Research Support; Current; Medtronic. Speaker's Bureau; Ended; Sanofi. Advisory Panel; Ended; Sanofi. Research Support; Current; Sanofi. Speaker's Bureau; Ended; Novo Nordisk A/S, Eli Lilly and Company. Consultant; Current; DreaMed Diabetes, Ltd., Radella Pharma. M.B. Zemel: None. Funding This study was funded entirely by Radella Pharmaceuticals
No takes yet. Share an insight, caveat, or question.
TIROSH et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: